Q-omics provides the consensus-scored RHBDF2 profile across patient tissues and cancer cell-line models. RHBDF2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RHBDF2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, RHBDF2 protein abundance shows 23,932 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where RHBDF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHBDF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHBDF2 survival associations across molecular data types. RHBDF2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHBDF2 RNA expression–survival associations across cancer types. High RHBDF2 expression shows unfavorable associations in KIRC, KIRP, LIHC, UCS and LGG, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RHBDF2 RNA expression.
This table summarizes RHBDF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RHBDF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHBDF2 shows higher tumor expression in KIRC, HNSC, KIRP, COAD, BLCA and LIHC. The KIRC box plot shows higher RHBDF2 RNA expression in tumor versus normal tissue (log2 FC = +1.966, t-test p < 0.001).
This table shows molecular features associated with RHBDF2 in patient tissues and cancer cell lines. In patient samples, RHBDF2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RHBDF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
